Hva tror du selskapet skal fokusere på? Hva er det Spetalen pønsker på her?
Ingen peiling, derfor jeg solgte. + at jeg fikk 14øre for TRene mens aksjer går for rundt 20øre nå 
2 Likes
Spetalen har vel alltids noen Ess i ermet. Tenker det kan bli en høy avkastning kortsiktig-
1 Like
4 Likes
“høy” avkastning er relativ. BIonor var et case hvor 10-20X avkastning var mulig. Spetalen har allerede doblet pengene sine. Og det kan godt være de dobles igjen innen kort tid.
1 Like
Ser noen mener Høie kun har solgt for å dekke sin andel i emmisjonen. Personlig aner jeg ikke og har solgt alt.
I og med at han har solgt tegningsretter også, så er det sannsynligvis ikke bare for å få penger til å kjøpe mer. Jeg tipper han reduserer sin andel nå som Spetalen har kontroll. Høie vet at det er sannsynlig at Spetalen kommer til å gjøre om på hele selskapet, og muligens selge ut HIV-forskiningen og drive med noe helt annet.
Jeg er litt overrasket over at dette er bedre enn det Solomon prøvde å få til i USA
1 Like
Han har soglt 25mill aksjer ( av 75mill) og 20mill TRer av 112mill.
1 Like
Det samme undres jeg veldig over. Så ikke helt den komme.
1 Like
Høyt volum i dag, og ca 32% opp. Hva er tankene til folket her inne?
Min ide har vært at salg på rundt 40 øre og kjøpe fra 20 øre og nedover ville være lurt. Når jeg leste at det er stor usikkerhet rundt hva driften vil bestå av videre, så valgte jeg likevel å ikke kjøpe da den touchet innom 20 øre. Ser ingen grunn til å kjøpe her når den allerede har steget såpass mye og jeg valgte å ikke kjøpe på “lav” kurs av fundamentale grunner.
2 Likes
Enig med du, tror mange kjøper fordi spettet har kjøpt.
1 Like
Disclosure obligation - Bionor Pharma ASA
Tekst
(a)
the name of the issuer of the shares,
Bionor Pharma ASA (ISIN: NO0003106700)
(b)
the date on which the proportion of shares held
reached, exceeded or fell below the thresholds set in
the Securities Trading Act section 4-3 subsection (1),
2016-09-15
©
name of the entity subject to the disclosure
obligation, including the name of the shareholder,
Swedbank Robur Fonder AB
Funds:
Ny Teknik
Fond (Kortnamn: BTI)
(d)
the number of shares the notification encompasses,
Shares: 18.496.834 2.15%
Warrants 21.185.312: 2.46%
Subscription rights: 28.929.793 3.36%
(e)
the subsequent situation with regard to voting rights,
including the percentage of the votes and shares of
the company held by the entity concerned,
Votes (%):2,15
Shares (%):2,15
(f)
what percentage of the votes and shares of the company
the entity concerned holds in the form of rights to
shares,
5.82% Total amount of rights in warrants and
subscription rights.
7.97% Total amount of shares and rights.
(g)
the circumstance that triggered the disclosure
obligation and whether such circumstance applied to
the entity concerned himself or to any related party
as mentioned in the Securities Trading Act section 2-5,
Rights Issue and increase of share capital in the
company.
(h)
the chain of controlled undertakings through which the
shares or rights are owned,
Fund management
(i)
where the notification concerns rights to shares as
mentioned in the Securities Trading Act section 4-3
subsection (4) the notification shall also contain a
description of the rights, including information on
the date and time that the rights will or can be
exercised and the date and time of their expiry.
The Norwegian Financial Supervisory Authority
(the “NFSA”) has today approved the prospectus of the
Company dated 14 September 2016 (the “Prospectus”)
prepared in connection with (i) the listing on Oslo
Børs of 525,000,000 new shares issued in connection
with the Private Placement at a subscription price of
NOK 0.10 per share; and (ii) the Rights Issue and
listing of 525,000,000 new shares (“Offer shares”) at
a subscription price of NOK 0.10 per share with
transferable subscription rights for eligible
shareholders.
The subscription period for the Rights Issue will
commence on 15 September 2016 at 09:00 CET and will
end on 29 September 2016 at 16:30 CET
(the “Subscription Period”). (i)
where the notification concerns rights to shares as
mentioned in the Securities Trading Act section 4-3
subsection (4) the notification shall also contain a
description of the rights, including information on
the date and time that the rights will or can be
exercised and the date and time of their expiry.
1 Like
Hvorfor ligger tegningsretter på 0,14 mens kursen er 0,29? TR 0,14 + emikurs 0,10 blir 0,24 for aksjen etter 29/9. Det virker mye med 5 øre i differanse.
2 Likes
Følger med på Bionor. ASC kjøpte alle tegningsretter på 0,14, nærmere 2,3 mill. Kursen har ligget rundt 0,13 denne uken. Torsdag er siste dag for å kjøpe.
2 Likes
Emisjonen 114% overtegnet
30.09.2016 07:00:53: Bionor Pharma - Preliminary result of the rights issue
BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
Bionor Pharma - Preliminary result of the rights issue
(Oslo, Norway, 30 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).
The subscription period of the Rights Issue expired 29 September 2016 at 16:30 CET. A preliminary counting of the subscriptions indicates that approximately 1.126 million shares have been subscribed out of a total of 525 million shares available, i.e. an oversubscription of approximately 114.5%. The gross proceeds from the Rights Issue will be NOK 52.5 million.
Allocation of shares in the Rights Issue will be resolved on or about 4 October 2016 by the Board of Directors of Bionor in accordance with the allocation criteria set out in the Prospectus. The final result of the Rights Issue is expected to be published on or about 4 October 2016. Letters of allocation will be distributed to investors giving notification of allocated new shares and the corresponding amount to be paid by each subscriber.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
3 Likes
Noen som husker hvilken dato en trekkes for aksjene?
Jeg tror det er 7.
1 Like
Yooho, hadde rett til 700k men fikk alle 1,1 mill jeg tegnet for. Tror dette kan bli bra jeg.
Så da gjelder det bare å ha dekning på kontoen om et par dager.
5 Likes
Lykke til. Blir bra det når Bionor står i krona 
2 Likes